LXS-196 | B2092

LXS-196 is an orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, LXS-196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells.

LXS-196 is an orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, LXS-196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells.

B2092 | LXS-196 DataSheet

Alternate Name/Synonyms: 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide; NVP-LXS196

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 1874276-76-2

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₂H₂₃F₃N₈O

Molecular Weight: 472.5

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent protein kinase C (PKC) inhibitor

MDL Number: N/A

PubChem CID: 118873253

SMILES: CC1(CCN(CC1)C2=C(N=CC=C2)NC(=O)C3=NC(=CN=C3N)C4=C(C=CC=N4)C(F)(F)F)N

InChi: InChI=1S/C22H23F3N8O/c1-21(27)6-10-33(11-7-21)15-5-3-9-29-19(15)32-20(34)17-18(26)30-12-14(31-17)16-13(22(23,24)25)4-2-8-28-16/h2-5,8-9,12H,6-7,10-11,27H2,1H3,(H2,26,30)(H,29,32,34)

InChi Key: XXJXHXJWQSCNPX-UHFFFAOYSA-N